CN103159687A - 一种2-胺基吡嗪-5甲酸的合成方法 - Google Patents
一种2-胺基吡嗪-5甲酸的合成方法 Download PDFInfo
- Publication number
- CN103159687A CN103159687A CN2013101258092A CN201310125809A CN103159687A CN 103159687 A CN103159687 A CN 103159687A CN 2013101258092 A CN2013101258092 A CN 2013101258092A CN 201310125809 A CN201310125809 A CN 201310125809A CN 103159687 A CN103159687 A CN 103159687A
- Authority
- CN
- China
- Prior art keywords
- reaction
- pyrazine
- formic acid
- amido
- trimethyl carbinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 title abstract description 9
- 238000001308 synthesis method Methods 0.000 title abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000006243 chemical reaction Methods 0.000 claims abstract description 20
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims abstract description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 7
- 238000006698 hydrazinolysis reaction Methods 0.000 claims abstract description 5
- -1 2-ethyl Chemical group 0.000 claims description 11
- 238000010189 synthetic method Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 235000010288 sodium nitrite Nutrition 0.000 claims description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- ACRZNTLZKYINII-UHFFFAOYSA-N 2-methylpropan-2-ol 1,2-xylene Chemical compound CC(C)(O)C.CC1=C(C=CC=C1)C ACRZNTLZKYINII-UHFFFAOYSA-N 0.000 claims description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- PHUICQXZWAAKAQ-UHFFFAOYSA-N benzene;2-methylpropan-2-ol Chemical compound CC(C)(C)O.C1=CC=CC=C1 PHUICQXZWAAKAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000006227 byproduct Substances 0.000 claims description 2
- 238000006193 diazotization reaction Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 abstract 2
- FRBQRJYLJGSANA-UHFFFAOYSA-N C(=O)(OC(C)(C)C)C=1N=CC(=NC1)N.C(=O)OCC Chemical compound C(=O)(OC(C)(C)C)C=1N=CC(=NC1)N.C(=O)OCC FRBQRJYLJGSANA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004317 sodium nitrate Substances 0.000 abstract 1
- 235000010344 sodium nitrate Nutrition 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- AFZSMODLJJCVPP-UHFFFAOYSA-N dibenzothiazol-2-yl disulfide Chemical compound C1=CC=C2SC(SSC=3SC4=CC=CC=C4N=3)=NC2=C1 AFZSMODLJJCVPP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开一种2-胺基吡嗪-5-甲酸的新合成方法,以易得的2,5-二甲酸乙酯吡嗪发生肼解发应,使单酯被肼解,同亚硝酸钠溶液反应,然后在甲苯和叔丁醇中回流得到关键中间体2-甲酸乙酯-5-Boc-胺基-吡嗪,再在盐酸中回流得2-胺基吡嗪-5-甲酸。本方法反应条件温和、简单,成本低,收率高,操作简便,适合于工业生产,具有极强的经济意义。
Description
技术领域
本发明涉及一种2-胺基吡嗪-5-甲酸的新合成工艺,属于医药、化工技术领域。
背景技术
吡嗪及其衍生物是化工产业和医药产业之间承上启下的重要中间体,广泛应用于医药、农药、染料、表面活性剂、橡胶硫化促进剂、抗氧剂、防腐剂等领域。
2-胺基吡嗪-5-甲酸是一种吡嗪衍生物,可以用来合成治疗糖尿病的药物(JMC2012,55,1318-1333);也可以用来合成治疗过敏、发炎和心血管疾病的药物(WO2012027322)。
文献报道的合成方法有如下:
路线A(JACS1949,71,2798-2800)
路线B(Helvetica Chimica Acta1964,47,873-6)
路线C(Rec.trav.chim.1962,81,282-286)
在路线A中,最后一步反应需要使用剧毒的氰化钾,反应高温(175℃),反应时间16小时,发应产物复杂,产率低。
在路线B中,原料不易得,须要用氧化剂高锰酸钾,最后一步脱酸反应需要高温,产率偏低。
在路线C中,原料不易制备,在脱保护基Cbz时,需用Pd/C,成本高,容易起火。
综合比较上述三条路线,发现所用的试剂剧毒或强氧化性,对环境污染大,反应需要高温,不易控制,起始原料不易制备,需用贵金属等,成本高,不适合放大生产。
发明内容
本发明目的是选择了一条新的合成路线来制备2-胺基吡嗪-5-甲酸,该路线原料易得、价廉,产率高,反应条件温和,适合于工业 生产,具有极强的经济意义。
合成路线如下:
本发明所述2-胺基吡嗪-5-甲酸的合成方法,在合成2-甲酸乙酯-5-甲酰肼吡嗪(化合物2)中:由于原料中有两个乙酯,容易双酯被肼解,得到副产物,因此水合肼需要慢慢滴加,反应溶剂包含但不限于无水乙醇、无水四氢呋喃、二氧六环、异丙醇、正丁醇和乙腈等,其中以无水乙醇为佳;反应温度可以在0℃至室温。
本发明所述2-胺基吡嗪-5-甲酸的合成方法,在合成2-甲酸乙酯-5-甲酰叠氮吡嗪(化合物3)中:上述反应所得的酰肼同亚硝酸钠水液和6N盐酸在0至5℃发生重氮化反应,反应完后需立即用二氯甲烷萃取,也可以用氯仿或二氯乙烷。
本发明所述2-胺基吡嗪-5-甲酸的合成方法,在合成2-甲酸乙酯-5-Boc-胺基-吡嗪(化合物4)中:发生Curtius重排反应,反应溶剂包含但不限于叔丁醇、甲苯-叔丁醇、二甲苯-叔丁醇或苯-叔丁醇;反应温度在70至110℃。
本发明所述2-胺基吡嗪-5-甲酸的合成方法,在合成2-胺基吡 嗪-5-甲酸中:主要是酯解和脱Boc,反应可以在盐酸溶液中回流进行;也可以先用碱(NaOH或KOH)加热酯解,再在三氟乙酸中室温反应脱去Boc。
本发明与现有技术相比具有如下的有益效果:
1、本发明采用2,5-二甲酸乙酯吡嗪为原料,其价格低、易得,从而降低了成本。
2、关键中间体2-甲酸乙酯-5-Boc-胺基-吡嗪具有好的稳定性,容易纯化,进入下一步反应的杂质少,合成最终产品2-胺基吡嗪-5-甲酸的纯度高。
3、整个反应路线条件温和,无需硅胶层析分离,缩短了生产过程,适合于工业化生产。
具体实施方式
实施例1:合成2-甲酸乙酯-5-甲酰肼吡嗪(化合物2)
2,5-二甲酸乙酯吡嗪(85g,0.38摩尔)溶于无水乙醇(1500毫升)中,冰浴条件下,慢慢滴加85%水合肼(22.3g,0.38摩尔),加毕在室温下搅拌过夜,抽滤,用无水乙醇(100毫升)洗涤,真空干燥得白色固体化合物(2)60g,产率:75.3%。mp:142-143℃
HNMR(DMSO-d6,400MHz):δ9.47(1H,s),9.23(1H,s),8.84(1H,s),4.55(2H,m),4.16(2H,m),1.47(3H,t).
实施例2:合成2-甲酸乙酯-5-甲酰叠氮吡嗪(化合物3)
2-甲酸乙酯-5-甲酰肼吡嗪(37g,0.18摩尔),加入二氯甲烷(600 毫升),水(600毫升),亚硝酸钠(60g,0.87摩尔),冰水冷却下,滴加6N HCl(250毫升),加完后,水相用二氯甲烷(200毫升x3)萃取,合并有机相,无水硫酸镁干燥,过滤,室温下水泵减压浓缩至干,得类白色固体化合物(3)33g,产率:82.9%。
实施例3:合成2-甲酸乙酯-5-Boc-胺基-吡嗪(化合物4)
2-甲酸乙酯-5-甲酰叠氮吡嗪(100g,0.45摩尔),加入甲苯(600毫升)和t-BuOH(100毫升),加热至回流,反应1小时,冷至室温,抽滤,甲苯(50毫升)洗涤,干燥得白色固体化合物(4)110g,产率:91.6%。mp:162-163℃
HNMR(DMSO-d6,400MHz):δ9.40(1H,s),8.95(1H,s),4.49(2H,m),1.57(9H,s),1.44(3H,t).
实施例4:合成2-胺基吡嗪-5-甲酸(化合物5)
2-甲酸乙酯-5-Boc-胺基-吡嗪(30g,0.11摩尔),加入4N HCl(750毫升),加热回流3小时,冷却,浓缩至干,加入水(40毫升),用2N NaOH溶液调至PH3,抽滤,将所得固体溶于热水,加入活性碳(0.5g),回流5分钟,抽滤,蒸去大部分水,固体析出,抽滤干燥得类白色固体2-胺基吡嗪-5-甲酸11g,产率:71.8%。mp:283℃(d)HNMR(DMSO-d6,400MHz):δ12.55(1H,s),8.49(1H,s),7.87(1H,s),7.25(2H,s)。
Claims (5)
1.本发明公开了以易得的2,5-二甲酸乙酯吡嗪发生肼解发应,再同亚硝酸钠溶液反应,然后在甲苯和叔丁醇中回流得到关键中间体2-甲酸乙酯-5-Boc-胺基-吡嗪,再在盐酸中回流得2-胺基吡嗪-5-甲酸。
2.如权利要求所述2-胺基吡嗪-5-甲酸的合成方法第一步,其特征在于:由于原料中有两个乙酯,非常容易双酯被肼解,得到副产物,而我们需要的是单酯被肼解,因此水合肼需要慢慢滴加,反应溶剂包含但不限于无水乙醇、无水四氢呋喃、二氧六环、异丙醇、正丁醇和乙腈等;反应温度在0℃至室温。
3.如权利要求所述2-胺基吡嗪-5-甲酸的合成方法第二步,其特征在于:第一步反应所得的酰肼同亚硝酸钠水液和盐酸发生重氮化反应,反应温度在0至5℃。
4.如权利要求所述2-胺基吡嗪-5-甲酸的合成方法第三步,其特征在于:发生Curtius重排反应,反应溶剂包含但不限于叔丁醇、甲苯-叔丁醇、二甲苯-叔丁醇和苯-叔丁醇;反应温度在70至110℃。
5.如权利要求所述2-胺基吡嗪-5-甲酸的合成方法第四步,其特征在于:酯解和脱Boc,反应可以在盐酸溶液中进行;也可以先用碱(NaOH或KOH)酯解,再在三氟乙酸中室温反应脱去Boc。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013101258092A CN103159687A (zh) | 2013-04-12 | 2013-04-12 | 一种2-胺基吡嗪-5甲酸的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013101258092A CN103159687A (zh) | 2013-04-12 | 2013-04-12 | 一种2-胺基吡嗪-5甲酸的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103159687A true CN103159687A (zh) | 2013-06-19 |
Family
ID=48583255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013101258092A Pending CN103159687A (zh) | 2013-04-12 | 2013-04-12 | 一种2-胺基吡嗪-5甲酸的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103159687A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024550A1 (en) * | 2007-08-20 | 2009-02-26 | N.V. Organon | N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators |
CN101460468A (zh) * | 2006-06-19 | 2009-06-17 | 霍夫曼-拉罗奇有限公司 | 2-吡嗪甲酰胺衍生物 |
US20090264416A1 (en) * | 2007-08-20 | 2009-10-22 | N.V. Organon And Pharmacopeia, Inc. | N-benzyl,n'-arylcarbonylpiperazine derivatives |
EP2145879A1 (en) * | 2008-07-11 | 2010-01-20 | Mallinckrodt Inc. | Pyrazine derivatives, methods of use, and methods for preparing same |
CN102977009A (zh) * | 2012-11-09 | 2013-03-20 | 杭州澳赛诺化工有限公司 | 一种2-三氟甲基-3-氟吡啶的合成方法 |
-
2013
- 2013-04-12 CN CN2013101258092A patent/CN103159687A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101460468A (zh) * | 2006-06-19 | 2009-06-17 | 霍夫曼-拉罗奇有限公司 | 2-吡嗪甲酰胺衍生物 |
WO2009024550A1 (en) * | 2007-08-20 | 2009-02-26 | N.V. Organon | N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators |
US20090264416A1 (en) * | 2007-08-20 | 2009-10-22 | N.V. Organon And Pharmacopeia, Inc. | N-benzyl,n'-arylcarbonylpiperazine derivatives |
EP2145879A1 (en) * | 2008-07-11 | 2010-01-20 | Mallinckrodt Inc. | Pyrazine derivatives, methods of use, and methods for preparing same |
CN102977009A (zh) * | 2012-11-09 | 2013-03-20 | 杭州澳赛诺化工有限公司 | 一种2-三氟甲基-3-氟吡啶的合成方法 |
Non-Patent Citations (1)
Title |
---|
VON E.FELDER等: "For the manufacture of 2-amino-5-pyrazinecarboxylic acid and derivatives", 《HELVETICA CHIMICA ACTA》, vol. 47, 31 December 1964 (1964-12-31) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107235923B (zh) | 一类3-芳基喹喔啉酮衍生物的制备方法 | |
CN102627573B (zh) | 5-氨基酮戊酸盐酸盐的合成方法 | |
CN111423382B (zh) | 一种替米沙坦关键中间体的制备方法 | |
CN102775358A (zh) | 6-氟-3-羟基-2-吡嗪酰胺的制备方法 | |
CN110305018A (zh) | 一种3-溴-2-氟硝基苯的制备方法 | |
CN103159687A (zh) | 一种2-胺基吡嗪-5甲酸的合成方法 | |
CN102786543A (zh) | 咪唑并[1,2-a]吡啶-6-硼酸频哪醇酯及其衍生物的制备方法 | |
CN117946104A (zh) | 一种水相中碘介导的吲哚并[2,3-b]喹啉类化合物的制备方法 | |
CN106243009B (zh) | 一种3-正丁胺基-4-溴-n-苯基马来酰亚胺的制备方法 | |
CN102690207B (zh) | 一种加巴喷丁的合成方法 | |
CN107176906A (zh) | 一种取代茚酮的合成方法 | |
CN107973755B (zh) | 一种3-乙酰氨基喹喔啉酮衍生物的制备方法 | |
CN114805360B (zh) | 一种替莫唑胺的制备方法 | |
CN115572231B (zh) | 一种双环[1.1.1]戊烷-1,3-二胺的盐的合成方法 | |
JPS61229852A (ja) | 1−メチル−5−ヒドロキシピラゾ−ルの製造法 | |
CN111518032A (zh) | 一种Gboxin的制备方法 | |
CN103483344B (zh) | 一种合成氧化吲哚类螺环化合物的方法 | |
CN117229206B (zh) | 一种碱催化合成多取代2-喹啉酮类化合物的制备方法 | |
CN113214197B (zh) | 一种维生素c乙基醚的制备方法 | |
CN112624966B (zh) | 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法 | |
CN107383023A (zh) | 一种6‑(2‑亚甲基喹啉)色胺酮类化合物及其合成方法 | |
CN116606238A (zh) | 一种N-Boc-3-硝基吲哚及其制备方法 | |
CN107602602A (zh) | 一种3‑氰基吡啶‑5‑硼酸频哪醇酯的合成方法 | |
CN107304171A (zh) | 一种奥司他韦的合成方法 | |
CA2207953A1 (en) | Process for the manufacture of acetonylbenzamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C05 | Deemed withdrawal (patent law before 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130619 |